Zobrazeno 1 - 10
of 58
pro vyhledávání: '"H. Roschitzki-Voser"'
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Autor:
Linda Coate, C.M. Yeo, G. Dimopoulou, J. de Castro, H. Roschitzki-Voser, Martin Früh, Solange Peters, E. Nadal, Rolf A. Stahel, S.M.S. Hashemi, Ross A. Soo, R. Bernabé, M. Provencio, Byoung Chul Cho, M.A. Sala, Sinead Cuffe, Barbara Ruepp, J-Y. Han, R. Garcia Campelo, Enric Carcereny
Publikováno v:
Annals of Oncology. 32:942-944
Autor:
S. Peters, J.-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier, K. Nackaerts, A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J.L. González Larriba, M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R.A. Stahel, C. Le Pechoux, D. De Ruysscher, R. Stahel, A. Hiltbrunner, M. Pardo-Contreras, A. Gasca-Ruchti, N. Giacomelli, R. Kammler, N. Marti, R. Pfister, A.C. Piguet, S. Roux, S. Troesch, M. Schneider, R. Schweri, I. Zigomo, Z. Tsourti, P. Zygoura, S. Tsouprou, M. Kassapian, G. Dimopoulou, C. Andriakopoulou, F. Morin, E. Amour, G. Mariaule, N. Archirel, M. Fernandez, E. Pereira, L. Benito, K. Lopez, A. Hernández, S. Chinchen, H. Jurkovic, A. Livingstone, J. Mitchell, M. Walker, S. Ng, C. Steer, K. Briscoe, A. Saqib, E. Abdi, B. Houghton, K. O’Byrne, B.R. Chittajallu, B.G. Hughes, A. Black, H. Werner, G. Zalcman, F. Vaylet, P. Merle, I. Monnet, N. Girard, P.-J. Souquet, F. Barlesi, D. Debieuvre, H. Senellart, M. Poudenx, A. Dixmier, D. Pouessel, J. Cadranel, H. Lena, E. Quoix, S. Friard, C. Audigier-Valette, E. Pichon, K. Kokowski, H. Kirchen, A. Tufman, C. De-Colle, J. de Langen, A. Insa, B. Massutí, M.P. Pulla, S.P. Aix, N. Villanueva, G.L. Vivanco, K. Franks, R. Califano
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ETOP/IFCT 4-12 STIMULI Collaborators 2022, ' Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial ', Annals of Oncology, vol. 33, no. 1, pp. 67-79 . https://doi.org/10.1016/j.annonc.2021.09.011
Annals of Oncology, 33(1), 67-79. Oxford University Press
BACKGROUND: Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25% to 33%. PATI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c0cd2636f83c5b87a3871c7a3d45ee
https://lirias.kuleuven.be/handle/123456789/682788
https://lirias.kuleuven.be/handle/123456789/682788
Autor:
U. Dafni, R.A. Soo, S. Peters, Z. Tsourti, K. Vervita, J-Y. Han, J. De Castro, L. Coate, M. Früh, S.M.S. Hashemi, E. Nadal, E. Carcereny, M. Angeles Sala González, R. Bernabé Caro, M. Provencio Pulla, S. Cuffe, B. Ruepp, H. Roschitzki-Voser, R. Rosell, R.A. Stahel
Publikováno v:
Annals of Oncology. 33:S46-S47
Autor:
Linda Coate, Zoi Tsourti, Gaston Demonty, Frederique Bustin, Daniel Rauch, H. Roschitzki-Voser, A. Pochesci, Veerle Surmont, M Guillot, Jakob Rudzki, Dunson Ejedepang, Isidoro Barneto Aranda, Baktiar Hasan, Rolf A. Stahel, Urania Dafni, Mary O'Brien, Hoi-Shen Radcliffe, Amina Scherz, Jacky Crequit, Deirdre O'Mahony, Sarah Danson, Solange Peters
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Introduction\ud \ud The efficacy of adding denosumab to standard first-line chemotherapy for advanced NSCLC patients has been evaluated in two separate randomised trials (SPLENDOUR and AMGEN-249). In this pooled analysis, we will assess the combinati
Autor:
Zoi Tsourti, Nicolaus Andratschke, A. Becker, Enriqueta Felip, Ernest Nadal, Rolf A. Stahel, Matthias Guckenberger, H. Roschitzki-Voser, Ruth Álvarez, Adrian Gasca-Ruchti, Solange Peters, Urania Dafni, Maarten Lambrecht, H. Vees, Miklos Pless, Amanda Tufman, Johan Vansteenkiste, Alex Martinez-Marti, A.-C. Piguet, Dirk De Ruysscher
Publikováno v:
Peters, S, Felip, E, Dafni, U, Tufman, A, Guckenberger, M, Álvarez, R, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Lambrecht, M, Andratschke, N, Tsourti, Z, Piguet, A-C, Roschitzki-Voser, H, Gasca-Ruchti, A, Vansteenkiste, J, Stahel, R A & de Ruysscher, D 2021, ' Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC : Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) ', Journal of Thoracic Oncology, vol. 16, no. 2, pp. 278-288 . https://doi.org/10.1016/j.jtho.2020.10.129
Journal of Thoracic Oncology, 16(2), 278-288. Elsevier Science
Journal of Thoracic Oncology, 16(2), 278-288. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology, 16(2), 278-288. Elsevier Science
Journal of Thoracic Oncology, 16(2), 278-288. International Association for the Study of Lung Cancer
INTRODUCTION: The NICOLAS study is the first completed single-arm phase II trial in stage III NSCLC evaluating hierarchically first the safety and then the efficacy of adding nivolumab concurrently to standard definitive concurrent chemoradiotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3688b7e198f0cac9727399400a9dcdc8
https://research.vumc.nl/en/publications/5cbb09d1-f28c-41dc-82db-7737694694e0
https://research.vumc.nl/en/publications/5cbb09d1-f28c-41dc-82db-7737694694e0
Autor:
Johan Vansteenkiste, Amanda Tufman, M. Guckenberger, Dirk De Ruysscher, Miklos Pless, N. Andratschke, Maarten Lambrecht, Alex Martinez-Marti, Antonio Irigoyen, M. Kassapian, A.-C. Piguet, H. Roschitzki-Voser, Enriqueta Felip, Manuela Rabaglio-Poretti, Rolf A. Stahel, Urania Dafni, Claus Belka, H. Vees, Solange Peters, E. Nadal, A. Becker
Publikováno v:
Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, A C, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, R A, Vansteenkiste, J & De Ruysscher, D 2019, ' Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial ', Lung Cancer, vol. 133, pp. 83-87 . https://doi.org/10.1016/j.lungcan.2019.05.001
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material
Autor:
W.-D. Janthur, Solange Peters, R. Shah, E. Nadal, David Gilligan, Sanjay Popat, R. López Castro, H. Roschitzki-Voser, Arup Roy, S. Rusakiewicz, A. Pope, James Spicer, Alessandra Curioni-Fontecedro, Patricia Fisher, Igor Letovanec, Varvara Polydoropoulou, Mary O'Brien, Oliver Gautschi, A. Gasca-Ruchti, Rolf A. Stahel, Urania Dafni, R. García Campelo, Barbara Ruepp
Publikováno v:
Annals of oncology, vol. 31, no. 12, pp. 1734-1745
Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6f837ec9c55fa71b6f276b35f45c97
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
Autor:
Niki Karachaliou, Zoi Tsourti, Bartomeu Massuti, Santiago Ponce Aix, Martin Früh, Miklos Pless, Paolo Bidoli, Núria Jordana-Ariza, Ariadna Balada-Bel, H. Roschitzki-Voser, Enriqueta Felip, Solange Peters, Mónica Garzón-Ibáñez, Roswitha Kammler, Ramon Palmero, Sinead Cuffe, Clara Mayo-de-las-Casas, Rafael Rosell, Sanjay Popat, Enric Carcereny, M.A. Molina-Vila, Oliver Gautschi, Beatriz García-Peláez, Rolf A. Stahel, Urania Dafni, Alessandra Curioni Fontecedro
Publikováno v:
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Introduction: Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994673a7e864203d23813318e7ec156a
http://hdl.handle.net/10281/260723
http://hdl.handle.net/10281/260723
Autor:
H. Roschitzki-Voser, Gillian Price, Rolf A. Stahel, Sinead Cuffe, Urania Dafni, Sarah Danson, Barbara Ruepp, Linda Coate, Roger von Moos, Mariano Provencio, Oliver Gautschi, Miklos Pless, Katja Mohorcic, Margarita Majem, Delvys Rodriguez-Abreu, Lionel Falchero, Bartomeu Massuti Sureda, Andrea Luciani, Solange Peters, M. Cobo, Jose Garcia Sanchez, Ingel K. Demedts, Alessandra Curioni-Fontecedro, Kurt G. Tournoy, Baktiar Hasan, Michael Mark, A. Pochesci, Manuela Rabaglio, Niels Reinmuth, Christoph C. Zielinski, Mary O'Brien, Daniel Betticher, Ana Laura Ortega Granados, Benjamin Besse, Isabelle Monnet, Jose Antionio Macias, Teresa Moran, Jessica Menis
Publikováno v:
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
BASE-Bielefeld Academic Search Engine
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
BASE-Bielefeld Academic Search Engine
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
Introduction: Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f11ec141e54ab0cd5ed8503a4a2a09f9
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6552
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6552